- Home
- IXHL vs XGN Comparison
IXHL vs XGN Comparison
Compare IXHL & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IXHL | XGN |
|---|---|---|
| Founded | 2001 | 2002 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.6M | 74.6M |
| IPO Year | 2024 | 2014 |
Fundamental Metrics
Financial Performance| Metric | IXHL | XGN |
|---|---|---|
| Price | $3.12 | $2.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.14 |
| AVG Volume (30 Days) | ★ 3.6M | 303.5K |
| Earning Date | 02-13-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,000.00 | N/A |
| Revenue This Year | N/A | $12.51 |
| Revenue Next Year | N/A | $13.23 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.11 | $2.96 |
| 52 Week High | $6.39 | $12.23 |
Technical Indicators
Market Signals| Indicator | IXHL | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 54.65 | 31.71 |
| Support Level | $0.32 | N/A |
| Resistance Level | $5.17 | $3.89 |
| Average True Range (ATR) | 0.50 | 0.26 |
| MACD | -0.16 | 0.02 |
| Stochastic Oscillator | 6.78 | 9.92 |
Price Performance
Historical ComparisonAbout IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.